nafamostat has been researched along with Esophageal Neoplasms in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 47-year-old male with esophageal cancer, who received 3 units of packed red cells and 20 units of platelet concentrates from 5 unrelated donors, was diagnosed as having PT-GVHD on the basis of typical clinical features, HLA typing of the patient and the responsible donor, and a mixed chimera of CD8+ lymphocytes on microsatellite DNA polymorphism analysis." | 1.30 | Treatment of post-transfusion graft-versus-host disease with nafmostat mesilate, a serine protease inhibitor. ( Hashimoto, M; Juji, T; Kohsaki, M; Okada, M; Ryo, R; Saigo, K; Tadokoro, K; Watanabe, N; Yasufuku, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ryo, R | 1 |
| Saigo, K | 1 |
| Hashimoto, M | 1 |
| Kohsaki, M | 1 |
| Yasufuku, M | 1 |
| Watanabe, N | 1 |
| Okada, M | 1 |
| Tadokoro, K | 1 |
| Juji, T | 1 |
1 other study available for nafamostat and Esophageal Neoplasms
| Article | Year |
|---|---|
Treatment of post-transfusion graft-versus-host disease with nafmostat mesilate, a serine protease inhibitor.
Topics: Benzamidines; Blood Donors; CD8-Positive T-Lymphocytes; DNA; Erythrocyte Transfusion; Esophageal Neo | 1999 |